(Q28219591)

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

Medical treatment of peripheral arterial disease and claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Peripheral arterial disease in people with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Peripheral arterial disease detection, awareness, and treatment in primary care

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Peripheral arterial disease in diabetic patients selected from a primary care setting: Implications for nursing practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Biochemistry and molecular cell biology of diabetic complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

A novel role for CD36 in VLDL-enhanced platelet activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Risk factors for progression of peripheral arterial disease in large and small vessels

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Does the clinical examination predict lower extremity peripheral arterial disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Utility and barriers to performance of the ankle brachial index in primary care practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Multi-bed vascular disease and atherothrombosis: scope of the problem

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

An Analysis of the Effectiveness of Interventions Intended to Help People Stop Smoking

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Antiplatelet therapy in peripheral arterial disease. Consensus statement

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Long-term results of peripheral arterial disease rehabilitation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Cilostazol: treatment of intermittent claudication

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021

Underdiagnosis of peripheral neuropathy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0823

7 January 2021